Evidence map›Paper›PMID 40859956›Full record

ReviewMedComm2025

Nanocarrier-Based Systems for Targeted Delivery: Current Challenges and Future Directions.

Zichen Xu, Yongyi Xie, Wenjie Chen, Wei Deng

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in MedComm, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Zichen XuSchool of Biomedical Engineering University of Technology Sydney Ultimo NSW Australia.ORCID https://orcid.org/0009-0009-8712-1617
Yongyi XieGuangdong Province & NMPA & State Key Laboratory School of Pharmaceutical Sciences Department of Emergency The Second Affiliated Hospital Guangzhou Medical University Guangzhou China.
Wenjie ChenGuangdong Province & NMPA & State Key Laboratory School of Pharmaceutical Sciences Department of Emergency The Second Affiliated Hospital Guangzhou Medical University Guangzhou China.ORCID https://orcid.org/0000-0001-9512-9664
Wei DengSchool of Biomedical Engineering University of Technology Sydney Ultimo NSW Australia.ORCID https://orcid.org/0000-0002-9413-0978

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanomaterials have become promising platforms in the field of drug and gene delivery, offering unique advantages over traditional therapeutic approaches. Their tunable physicochemical properties enable improved pharmacokinetics and therapeutic performance. A wide range of nanocarriers, including lipid-based, polymer-based, and hybrid systems, have been rapidly developed and are attracting increasing attention in both preclinical and clinical research. However, despite promising preclinical outcomes, these systems still encounter critical challenges in achieving precise delivery to specific tissues, cells, and intracellular compartments. This review provides a comprehensive assessment of recent advances in the design and application of nanocarriers for targeted delivery, with emphasis on strategies designed for nuclear targeting. In the context of nuclear targeting, it explores passive approaches involving modulation of particle size, morphology, and surface charge, alongside active targeting strategies incorporating nuclear localization signals and other ligands. In addition to highlighting progress, the review examines the limitations associated with delivery efficiency, off-target effects, and barriers to clinical translation. By addressing both advances and ongoing challenges, this review provides valuable insights into the design and engineering of targeted nanocarriers. These developments are crucial for unlocking the full potential of precision nanomedicine.

Indexed as

active targetingdrug and gene deliverynanocarriernuclear localization signalsnuclear targetingtargeted delivery

Identifiers

PMID40859956
PMCPMC12371215

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.